Solvent‐Free Preparation of Pharmaceutically Active Diindolylmethane Derivatives by Stable Triple‐Interpenetrated Heterometallic‐Organic Frameworks With Sc‐Pd/Pt Synergistic Sites

Why It Matters

The breakthrough offers a greener, highly efficient route to pharmaceutically relevant DIM derivatives, reducing solvent waste and lowering production costs for drug manufacturers.

Key Takeaways

• Triple‑interpenetrated HMOFs enable solvent‑free Friedel‑Crafts reactions
• Sc‑Pd/Pt synergistic sites deliver up to 99% product yield
• First MOF‑catalyzed structural confirmation of DIM‑C‑pPhOCH3
• Computational data reveal dual‑metal cooperative mechanism
• One‑pot synthesis simplifies scalable production of noble‑metal HMOFs

Pulse Analysis

The emergence of heterometallic‑organic frameworks (HMOFs) marks a pivotal shift toward sustainable catalysis in fine‑chemical synthesis. By integrating readily tunable metal nodes with robust organic linkers, HMOFs combine the selectivity of homogeneous catalysts with the recyclability of heterogeneous systems. This duality addresses long‑standing challenges in drug manufacturing, where solvent‑intensive processes inflate costs and environmental footprints. Recent advances in ligand design, especially bifunctional acids like 4‑picolinic acid, have unlocked rapid assembly of complex architectures that were previously inaccessible due to sluggish noble‑metal ligand exchange.

In the study at hand, researchers engineered Sc‑Pd and Sc‑Pt frameworks featuring triple‑interpenetrated networks and unique Sc₃(µ₃‑O)(COO)₆ clusters. The resulting materials—ScPd‑INA, ScPt‑INA and ScPt‑MCA—exhibited exceptional catalytic performance, delivering up to 99% conversion in solvent‑free Friedel‑Crafts alkylation of diindolylmethane precursors. Notably, the team isolated four crystalline products, including the pharmacologically active DIM‑C‑pPhOCH3, whose structure was elucidated by single‑crystal X‑ray diffraction for the first time using an MOF catalyst. Theoretical calculations highlighted a synergistic mechanism where the Lewis‑acidic Sc centers activate the electrophile while the noble metal sites facilitate C‑C bond formation, explaining the observed rate acceleration and durability.

The implications for the pharmaceutical sector are substantial. Solvent‑free protocols cut downstream purification steps, lower hazardous waste, and improve overall process economics. Moreover, the one‑pot synthesis of these HMOFs simplifies scale‑up, offering a cost‑effective alternative to traditional homogeneous noble‑metal catalysts that require expensive ligands and stringent handling. As the industry pivots toward greener manufacturing, platforms like Sc‑Pd/Pt HMOFs could become standard tools for constructing complex drug molecules, accelerating time‑to‑market while meeting stricter regulatory and sustainability benchmarks.